Important public health conversations about GLP-1 drugs are happening at all levels of the health system from policymakers to patients -- and everyone in between. We recently partnered with Blue Cross Blue Shield Association on their report that revealed people aren’t staying on GLP-1 drugs long enough to see meaningful weight loss. Our Real-World Solutions team, led by Henriette C., is committed to continuing to create data-driven insights that will help better inform how these medications are used to achieve the best possible outcomes.
Glucagon-like peptide 1 agonists, or GLP-1 drugs, help people with Type 2 diabetes and obesity lower their blood sugar and promote weight loss, and are now a household name. “It’s everywhere,” Dr. Razia Hashmi, Blue Cross Blue Shield Association (BCBSA) vice president of clinical affairs, said at #FortuneHealth. “It’s part of our conversation. It’s on social media, your family’s talking about it, we’re talking about it in the boardroom, we’re talking about it in the break room. There is, obviously, a lot of excitement about it—the adoption’s been exponential—but there is so much more to learn.” Not all of it is positive, as revealed by a new study conducted by Blue Health Intelligence that examined 170,000 GLP-1 users who were prescribed the medication for weight loss. Released Tuesday, it’s “the largest-ever study done, real-world evidence study” of the medication, Hashmi said. Read more: https://lnkd.in/eD6c8AhB
